source
- After Apellis deal, Biogen looks to fill early-stage pipelineBiogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and res…Endpoints · 3mo ago↗ source
- AstraZeneca rekindles UK relationship, pledges £300M to expandAstraZeneca and the UK government are back in each other's good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a £300 million budget to finish construction of a n…Endpoints · 3mo ago↗ source
- Chiesi signs $1.9B deal to acquire KalVista and its approved drugChiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…